Altimmune Inc (ALT NASDAQ) stock market data APIs
$3.8832
0.04(1%)
as of March 10, 2026
Try our APIs with
free plan!
Altimmune Inc Financial Data Overview
Price chart is built with
Anychart
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Prev. Close
3.8832
Open
3.9232
High
4.0237
Low
3.8624
52 wk Range
2.9-7.73
Market Cap
486 M
Shares Outstanding
125 M
Revenue
41 000
EPS
-0.21
Beta
0.17
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Altimmune Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Altimmune Inc data using free add-ons & libraries
Get Altimmune Inc Fundamental Data
Altimmune Inc Fundamental data includes:
- Net Revenue: 41 000
- EBITDA: -94 377 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.27
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Altimmune Inc News
New
Altimmune to start late-stage trial for MASH candidate this year
[Close up image of wooden cubes with alphabet Q4 on office desk.] mohd izzuan With its Q4 2025 financials on Thursday, Altimmune (ALT [https://seekingalpha.com/symbol/ALT]) announced plans to begin a...
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play
The weight-loss drug market has experienced incredible momentum over the past few years, and according to analyst projections, it hasn't peaked yet -- far from it. Among the many drugmakers looking to...
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today an...
UK Penny Stocks Spotlight: Altitude Group And 2 Additional Promising Picks
The United Kingdom's market has recently faced challenges, with the FTSE 100 index closing lower due to weak trade data from China, highlighting global economic interconnectedness. In such a fluctuati...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
